ADNI 3
OVERVIEW

OVERALL GOAL OF ADNI

To validate biomarkers for clinical AD trials

To standardize biomarkers for clinical AD trials

To optimize biomarkers for clinical AD trials

AD trials include Phase 2 (POC) and Phase 3

To provide all the data to those designing trials

To help create a world wide network for AD trials

Ultimately to facilitate development of of a surrogate biomarker outcome measure: tau?

ACCOMPLISHMENTS OF ADNI (21 months left)

Amyloid phenotyping with PET and CSF

Standardized methods for MRI, PET, and cognitive measurements

Provided data for designing trials

ADNI 3 AIMS

Continued followup of ADNI subjects

Enrollment of new controls, MCI, early AD

Computerized cognitive testing

Baseline and longitudinal tau PET

State of the art MRI; helpful for phase 2

Amyloid PET and FDG PET

CSF analysis

Genetics and Neuropathology

Standardization of all methods

WHAT IS UNIQUE ABOUT ADNI 3

ADNI 3 will be the only large multisite

STUDY DESIGN AND BUDGET

The design process has just begun

Some possible scenarios are presented for discussion

The balance of subjects is to be determined:

- Carrying some subjects forward; enrolling new
- Controls, MCI, AD Current ratio is 1:2:1
- This issue will be discussed in depth in Clinical Core discussion

Summary of ADNI III Subjects